Quantitative Analysis of Bacterial Toxin Affinity and Specificity for Glycolipid Receptors by Surface Plasmon Resonance*

(Received for publication, August 21, 1996, and in revised form, November 19, 1996)

C. Roger MacKenzie Dagger , Tomoko Hirama , Kok K. Lee , Eleonora Altman and N. Martin Young

From the Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada K1A 0R6

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

The primary virulence factors of many pathogenic bacteria are secreted protein toxins which bind to glycolipid receptors on host cell surfaces. The binding specificities of three such toxins for different glycolipids, mainly from the ganglioside series, were determined by surface plasmon resonance (SPR) using a liposome capture method. Unlike microtiter plate and thin layer chromatography overlay assays, the SPR/liposome methodology allows for real time analysis of toxin binding under conditions that mimic the natural cell surface venue of these interactions and without any requirement for labeling of toxin or receptor. Compared to conventional assays, the liposome technique showed more restricted oligosaccharide specificities for toxin binding. Cholera toxin demonstrated an absolute requirement for terminal galactose and internal sialic acid residues (as in GM1) with tolerance for substitution with a second internal sialic acid (as in GD1b). Escherichia coli heat-labile enterotoxin bound to GM1 and tolerated removal or extension of the internal sialic acid residue (as in asialo-GM1 and GD1b, respectively) but not substitution of the terminal galactose of GM1. Tetanus toxin showed a requirement for two internal sialic acid residues as in GD1b. Extension of terminal galactose with a single sialic acid was tolerated to some extent. The SPR analyses also yielded rate and affinity constants which are not attainable by conventional assays. Complex binding profiles were observed in that the association and dissociation rate constants varied with toxin:receptor ratios. The sub-nanomolar affinities of cholera toxin and heat-labile enterotoxin for liposome-anchored gangliosides were attributable largely to very slow dissociation rate constants. The SPR/liposome technology should have general applicability in the study of glycolipid-protein interactions and in the evaluation of reagents designed to interfere with these interactions.


INTRODUCTION

The protein toxins produced by many pathogenic bacteria are among the best characterized virulence factors. These toxins typically bind to oligosaccharide receptors on host cell surfaces (1). Many belong to the AB5 family of toxins which are comprised of an enzymatically active and toxic A-subunit and five B-subunits which form the receptor binding portion of the molecule. In most instances the five B-subunits are identical and allow for pentameric attachment to the cell surface receptors. Crystal structures of five AB5 toxins or their B-pentamers, three complexed with carbohydrate receptors, have been reported. These are cholera toxin (2, 3), Escherichia coli heat-labile toxin (4-6), shiga toxin (7), shiga-like toxin (8), and pertussis toxin (9). However, this wealth of structural data has not answered all questions relating to the oligosaccharide-binding specificities of these molecules. For example, there is some controversy as to the nature of the functional receptor of LT.1 Although structurally very similar to CT, LT shows subtle differences in receptor binding specificity (1). Whereas it is generally accepted that the ganglioside GM1 (Galbeta 1-3GalNAcbeta 1(NeuAcalpha 2-3)4Gal-beta 1-4Glc-ceramide) is the sole receptor for CT, it is thought that N-acetyllactosamine, presented on the poly-N-lactosamine series of glycoproteins (10, 11) or paragloboside (Galbeta 1-4GlcNAcbeta 1-4Galbeta 1-4Glc-ceramide) (12) may act a second receptor for LT.

To some extent, analysis of structure-activity relationships in these systems has been hampered by the largely qualitative nature of the assay methods employed. Whereas structural data can form the basis of the design of drugs to block toxin binding, accurate binding assay data are required for testing the effectiveness of such compounds. Apart from some titration microcalorimetry data for oligosaccharide and liposome-embedded ganglioside binding by CT (13, 14) and shiga-like toxin (15), all of the available information on toxin binding has been obtained using labeled materials in microtiter plate or thin layer chromatography overlay methods. Such methods do not yield affinity data and have associated uncertainties regarding oligosaccharide presentation and the effect of the labeling procedures on protein structure. It is well recognized that saccharide clustering is an important feature of protein-carbohydrate interactions and is necessary in order to accommodate the multivalent and precise geometric nature of many of these interactions. Rigid immobilization of glycoconjugates on solid surfaces is not an ideal way of presenting them in a natural fashion.

Recently, surface plasmon resonance has been applied to the analysis of CT binding to gangliosides which were directly self-assembled onto alkylthiol surfaces (16). The technique showed strong binding by CT to GM1, but the ganglioside specificity profile reported was generally not in good agreement with that obtained by other methods (1, 14) and that predicted by the crystal structure of the GM1-CTB-subunit complex (2). We have developed a technique in which individual glycolipid receptors are incorporated into artificial liposomes that also contain a small amount of lipopolysaccharide to allow the capture of these liposomes on SPR sensor chip surfaces via an immobilized anti-LPS monoclonal antibody. This permits label-free analysis of toxin binding to immobilized oligosaccharides under conditions that mimic the in vivo membrane surface venue of these interactions. We have used this technology to obtain kinetic and affinity constants to characterize the receptor specificities and affinities of CTB and LT and have shown that it can be applied also to the study of the clostridial neurotoxins, such as tetanus toxin. These toxins do not belong to the AB5 toxin group but are also known to bind to oligosaccharide receptors (17).


EXPERIMENTAL PROCEDURES

Materials

Ganglioside GM1 was obtained from BioCarb. All other glycolipids were obtained from Sigma. Cholera toxin B subunit (CTB) and TT C-fragment were obtained from Calbiochem and LT from Sigma. Dimyristoylphosphatidylcholine was purchased from Sigma. Salmonella essen serogroup B LPS was isolated by standard procedures (18). The anti-S. essen LPS monoclonal antibody SE155-4 IgG was purified from ascites fluid by affinity chromatography (19, 20).

Liposome Preparation

Mixtures containing 1 mg of DMPC and 10-100 µg of a single glycolipid in CHCl3/MeOH were dried in glass vials under N2. Vials were further dried under vacuum for at least 1 h, and 300 µl of phosphate-buffered saline containing 10 µg of Salmonella serogroup B LPS was then added to each vial. Vials were then vortexed vigorously and placed in a sonic bath for 20 s. Suspensions containing the liposomes were extruded (19 passes) through 50 nm polycarbonate membranes in a Liposofast apparatus (Avestin Inc., Ottawa, ON, Canada). Liposomes were separated from unincorporated material by passage through a 1-ml Sepharose CL-4B column. Liposome preparations were stored at 4 °C in 10 mM phosphate buffer, pH 7.0, containing 160 mM NaCl.

SPR Analysis

Binding kinetics were determined by SPR using a BIAcore 1000TM biosensor system (Biacore Inc., Piscataway, NJ) (21). Se155-4 IgG was immobilized on research grade CM5 sensor chips (Biacore Inc.) at a concentration of 50 µg/ml in 10 mM sodium acetate, pH 4.5, using the amine coupling kit supplied by the manufacturer. Approximately 5000 resonance units of IgG were immobilized under these conditions, where 1 RU corresponds to an immobilized protein concentration of ~1 pg/mm2 (22). Unreacted moieties on the surface were blocked with ethanolamine. All measurements were carried out in HEPES-buffered saline which contained 10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA. Analyses were performed at 25 °C and at flow rates of 5 or 10 µl/min for the determination of on-rates and equilibrium binding and 50 µl/min for the determination of off-rates. Liposome preparations obtained as described above were generally diluted 1:50 in HEPES-buffered saline for capture by the IgG surfaces. In all instances, toxin concentrations were calculated using the molecular weight of the whole toxin or toxin fragment and not on a per binding site basis. Surfaces were typically regenerated with 10 µl of 1 mM cholate in 10 mM acetate buffer, pH 4.5, followed by 5 µl of 4 mM cholate in the same buffer. Milder conditions (less cholate) were used in instances of less toxin binding.

Data Analysis

Association and dissociation rate constants were calculated by nonlinear fitting of the primary sensorgram data (23) using the BIAevaluation 2.0 software (Biacore Inc.). The dissociation rate constant is derived using the equation
R<SUB>t</SUB>=R<SUB>t0</SUB>e<SUP><UP>−</UP>k<SUB><UP>off</UP></SUB>(t<UP>−</UP>t<SUB>0</SUB>)</SUP> (Eq. 1)
where Rt is the response at time t, Rt0 is the amplitude of the initial response, and koff is the dissociation rate constant. Dissociation of two components can treated as the sum of two independent events where each is described by an equation of the above form. The association rate constant can then be derived using the equation
R<SUB>t</SUB>=<FR><NU>k<SUB><UP>on</UP></SUB>CR<SUB><UP>max</UP></SUB>(1−e<SUP><UP>−</UP>(k<SUB><UP>on</UP></SUB>C<UP>+</UP>k<SUB><UP>off</UP></SUB>)<SUP>t</SUP></SUP>)</NU><DE>k<SUB><UP>on</UP></SUB>C+k<SUB><UP>off</UP></SUB></DE></FR> (Eq. 2)
where Rt is the response at time t, Rmax is the maximum response, C is the concentration of ligate in solution, kon is the association rate constant, and koff is the dissociation rate constant. A two-component association is treated as the sum of two independent events, each described by an equation of the above form.

Affinities were calculated from rate constants and from analysis of equilibrium binding. By measuring equilibrium resonance units as a function of ligand concentration, binding data can be analyzed by Scatchard plots using the equation
<FR><NU>R<SUB>eq</SUB></NU><DE>C</DE></FR>=K<SUB>a</SUB>R<SUB><UP>max</UP></SUB>−K<SUB>a</SUB>R<SUB><UP>eq</UP></SUB> (Eq. 3)
where Req is the equilibrium resonance units, Rmax is the resonance signal at saturation, C is the concentration of free protein, and Ka is the association constant. A plot of Req/C versus C has a slope of -Ka.


RESULTS

Liposome Surfaces

Liposome surfaces generated by a capture mechanism involving Salmonella serogroup B LPS and Se155-4 IgG, which is specific for serogroup B LPS, were used to obtain profiles for toxin binding to a panel of glycolipids (Fig. 1). Typically, 1000 RU of liposomes prepared from mixtures containing 1% (w/w) LPS and 1-10% of selected glycolipids were captured by 5000 RU of IgG surfaces. There was complete retention of the liposomes by the IgG surface, thereby providing a stable baseline for the determination of toxin binding specificity and kinetics. An analysis cycle showing GM1 liposome capture, LT binding to the liposomes and surface regeneration is shown in Fig. 2. Liposomes containing only DMPC and serogroup B LPS were used as blank surfaces for the measurement of nonspecific binding. Liposomes containing only DMPC and LPS also provided a positive control for demonstrating the accuracy of the SPR/liposome format for measuring the kinetics of protein-sugar interactions. A dimeric single-chain Fv form of Se155-4 was bound to the LPS presented on the control liposome surface (data not shown) and nonlinear analysis of the data gave association rate and dissociation rate constants that were the same as those previously reported for the binding of this scFv (mutant B5-1), as determined by SPR using bovine serum albumin-O-polysaccharide surfaces (24).


Fig. 1. Structures of glycolipids used in liposome preparation.
[View Larger Version of this Image (19K GIF file)]



Fig. 2. Sensorgram showing the capture of liposomes containing 2% GM1, the binding of 50 nM LT to the liposomes and surface regeneration. A, begin injection of liposomes on an anti-liposome (LPS) surface; B, end of liposome injection; C, begin injection of LT; D, end injection of LT; E, begin surface regeneration; F, regenerated surface ready for next analysis cycle. Bulk change effects are visible at the beginning and end of the liposome and toxin injections.
[View Larger Version of this Image (13K GIF file)]


The IgG surfaces were typically stable to at least 100 regenerations using the cholate-acetate buffer regeneration protocol. One advantage to using Se155-4 as the capture antibody is that it dissociates from the LPS antigen at pH 4.5 (20), thereby permitting relatively mild surface regeneration conditions.

Toxin Binding Kinetics

The amount of glycolipid in the liposomes had a marked effect on the association phase of CTB binding to GM1. At CTB concentrations of 20 nM, more rapid association kinetics were observed with 1 and 2% GM1 liposomes than with 3 and 4% GM1 liposomes (Fig. 3A). Linear transformation of the sensorgram data showed the existence of two distinct on-rates for CTB binding to GM1 (Fig. 4A), but only the faster rate was observed at GM1 concentrations of 1 and 2%. This is reflected in the derivative plot (Fig. 4A) which shows linearity for the binding of 20 nM CTB to liposomes containing 1% GM1. Liposomes containing 2% glycolipid were used for kinetic analyses since they gave good levels of binding, attributable to the faster on-rate. At this glycolipid concentration, the association rate constants derived at different toxin concentrations were in good agreement (Table I). Association kinetics were not significantly affected by changes in toxin concentration, liposome density or flow rate indicating that there wasn't any mass transport limitation under these experimental conditions.


Fig. 3. Effect of glycolipid and toxin concentration on CTB binding to GM1 liposomes. A, overlay plot of 20 nM CTB binding to liposomes containing 1, 2, 3, and 4% GM1. B, overlay plot of 10 nM, 20 nM, 30 nM, and 50 nM CTB binding to liposomes containing 2% GM1.
[View Larger Version of this Image (21K GIF file)]



Fig. 4. Analysis of association and dissociation phases of CTB binding to GM1-containing liposomes. A, derivative plots of 20 nM CTB binding to liposomes containing 1% (open circle ) and 3% (bullet ) GM1 showing the presence of two distinct association rate constants; B, transformed data showing different off-rates for the dissociation of 10 nM (open circle ) and 50 nM (bullet ) CTB from liposomes containing 2% GM1; C, fitting of the association phase of 40 nM CTB binding to liposomes containing 2% GM1 to the BIAevaluation one-site model (A + B Right-arrow AB); D, fitting of the dissociation phase of 40 nM CTB binding to liposomes containing 2% GM1 to the BIAevaluation one-site model (AB Right-arrow  A + B).
[View Larger Version of this Image (26K GIF file)]


Table I.

Affinities and rate constants for toxin or toxin subunit binding to liposomes containing glycolipids that exhibit binding by SPR


Toxin or toxin subunit Ganglioside kon koff KDa

M-1 s-1 s-1 M
CTB GM1 6.2  × 105 (±5.5)b 4.5  × 10-4 (±18.3) 7.3  × 10-10 (±19.1)
GD1b 4.1  × 105 (±12.4) 3.1  × 10-3 (±17.4) 8.0  × 10-9 (±21.4)
LT GM1 4.2  × 105 (±22.1) 2.4  × 10-4 (±27.9) 5.7  × 10-10 (±35.6)
GD1b 7.4  × 105 (±8.0) 2.1  × 10-3 (±23.8) 3.0  × 10-9 (±25.1)
Asialo-GM1 4.7  × 105 (±17.4) 6.9  × 10-3 (±19.5) 1.5  × 10-8 (±26.1)
TT C-fragment GD1b 2.4  × 104 (±13.3) 3.6  × 10-3 (±2.1) 1.5  × 10-7 (±13.5)
GT1b 1.8  × 104 (±35) 3.1  × 10-3 (±17.6) 1.7  × 10-7 (±39.2)
GD2  ---c  ---  ---

a  koff/kon.
b  Numbers in brackets are the S.E., expressed as % (95% confidence limits) which for 1) on-rates were based on measurements at 5-7 different concentrations in each instance, 2) CTB and LT off-rates were based on 5 measurements at 10 nM toxin for GM1 and GD1b and 40 nM LT for asialo-GM1, and 3) TT off-rates were based on 5 measurements at 500 nM.
c  ---, low binding precluded accuracy of rate constant determination and calculation of affinity.

The dissociation rate constants for CTB binding to glycolipids were also influenced by toxin:receptor ratios. For example, at CTB concentrations of 20 nM faster off-rates were observed at liposomal GM1 concentrations of 1 and 2% than at higher concentrations. At constant receptor concentrations, higher toxin concentrations resulted in faster off-rates (Fig. 3B). Transformation of the dissociation data clearly shows these differences (Fig. 4B). Also, whereas there was some curvature to the transformed data plot at 50 nM CTB/2% GM1, the 10 nM CTB/2% GM1 plot was linear. Presumably, the slow off-rates resulted from pentavalent binding with the faster off-rates at low GM1 to toxin ratios reflecting a lower mean valency of binding. Nonlinear analysis of the rapid association data and slow dissociation data showed good fitting to a one to one interaction model (Fig. 4, C and D) even though multivalency leads to a more complex interaction than is described by such a model. The slow dissociation rates are given in Table I, and these values were used for the calculation of the KD values shown in Table I. The slow off-rates are at the lower end of the instrument range, and there is considerable error associated with their calculation because of the significant influence of even marginal baseline drift. To improve the accuracy of the off-rate calculations, analyses were performed on data for dissociation of at least 10% of the bound toxin.

Equilibrium Binding

For CTB, equilibrium binding studies were conducted as an alternative means of deriving affinities and determining the glycolipid concentrations that give optimal toxin binding. Scatchard plots of equilibrium data showed distinctly different binding profiles for liposomes containing 2 and 4% GM1 (Fig. 5). The equilibrium data were in good agreement with the calculated rate constants in that stronger binding was observed at the lower glycolipid concentration. The KD values derived from the Scatchard plots were 1.7 nM for 2% GM1 liposomes and 6.8 nM for 4% GM1 liposomes. The 1.7 nM value is also in reasonable agreement with the rate constant-derived KD value of 0.73 nM for the binding of CTB to 2% GM1 liposomes (Table I). A rate constant-derived affinity was not calculated for 4% GM1 liposomes because of the nonlinearity of the transformed association data at higher GM1 concentrations (Fig. 4A).


Fig. 5. Scatchard plots for the determination of affinities from equilibrium binding. 5-30 nM CTB was bound to liposomes containing 2% (open circle ) and 4% (bullet ) GM1.
[View Larger Version of this Image (11K GIF file)]


Binding Specificities and Affinities of CTB, LT, and TT

The profiles of CTB, LT, and TT C-fragment binding to different glycolipids are shown in Fig. 6. Both CTB and LT showed highest affinity for GM1 with an approximately 10-fold lower affinity for GD1b (Table I). In both instances, the lower affinity for GD1b was attributable to a faster off-rate. CTB showed insignificant specific binding to the other gangliosides that were tested (Fig. 6A). There was, however, some evidence of adsorption of CTB to liposome surfaces as the post-injection response on all liposomes (including the blank surface liposomes containing only DMPC and LPS) was higher than on the IgG capture surface. This nonspecific binding did not significantly influence on-rate calculations because it gave little response with time relative to the response for specific binding. However, with slow off-rates, such as those observed for CTB and LT binding to GM1, this low level nonspecific binding could influence the calculations and would have the effect of giving artifactually fast dissociation rate constants for the specific binding. LT differed from CT in that it showed some specificity for asialo-GM1 (Fig. 6B) with an affinity that was about 5 times lower than that observed for GD1b and 25 times lower than for GM1 (Table I).


Fig. 6. Specificities of toxins for different glycolipids. Sensorgrams showing 100 nM CTB (A), 500 nM LT (B), and 1 µM TT C-fragment (C) binding to liposomes containing different glycolipids at concentrations of 2% in each instance.
[View Larger Version of this Image (19K GIF file)]


Tetanus toxin C-fragment bound most strongly to GD1b (Fig. 6C) but with an affinity that was at least three orders lower than that of the preferred CTB and LT ligand, GM1 (Table I). Extension of the terminal galactose of GD1b with a single sialic acid, to give GT1b, resulted in a slight reduction in affinity, and the addition of two sialic acid residues to the galactose, to give GQ1b, completely abolished binding. Removal of one of the NeuAc residues from GD1b, to give GM1, abolished binding, but removal of the terminal galactose of GD1b, to give GD2, was tolerated to some extent.


DISCUSSION

The glycolipid binding assay described here has several attractive features. The SPR technology used to monitor binding gives kinetic data that are difficult to obtain by other means, and the kinetic data in turn can be used to obtain affinities for a wide variety of glycolipid-toxin complexes. The membrane environment of the interactions resembles physiological conditions more closely than TLC overlay and microtiter plate techniques, and this should help to eliminate the artifactual binding specificities that have been observed with the solid phase assays (25). The LPS/liposome capture methodology described here gives stable liposome retention throughout the binding cycle and has an efficient sensor chip surface regeneration protocol. Incorporation of a small amount of LPS in the liposomes was sufficient for complete liposome retention on the sensor chip. The nature of the LPS-antibody interaction permitted surface regeneration with 10 mM acetate, pH 4.5, containing cholate. Masson et al. (26) have reported the capture of biotinylated natural lipid vesicles by streptavidin, avidin, and anti-biotin antibody sensor chip surfaces but encountered rather rapid deterioration of these surfaces during regeneration.

The CTB and LT specificities determined by the SPR/liposome method are in excellent agreement with binding site features observed in crystal structures. The structure of CTB bound to the GM1 pentasaccharide (Galbeta 1-3GalNAcbeta 1(NeuAcalpha 2-3)4Galbeta 1-4Glc) revealed that the five oligosaccharide binding sites resided primarily within the individual B-subunits (2, 3). The binding was described as a two-fingered grip with the Galbeta 1-3GalNAc moiety representing the "forefinger" and sialic acid representing the "thumb" (2). The strongest toxin receptor interactions involve the terminal galactose which inserts into a deep pocket in the binding site and the sialic acid which occupies a shallower depression on the toxin surface. This is consistent with the lack of binding of CTB to asialo-GM1 and GM2 (Fig. 6A). The structure of LT complexed with lactose (Galbeta 1-4Glc) (4) revealed the binding site of the terminal galactose in the ganglioside GM1, which is known to bind to LT with high affinity. A comparison of the CT and LT structures has provided a possible explanation of the subtle differences in specificity observed for these two toxins (1-3). Whereas the His-13 residue in CT donates a hydrogen bond from its backbone amide to sialic acid with no side-chain contribution to binding, Arg-13, found at this position in most variants of LT, can also contribute side-chain binding to the GalNAcbeta 1-4Galbeta 1-4Glc portion of GM1 and other gangliosides. These structural features are in agreement with the binding profiles observed here (Fig. 6, A and B). Ganglioside binding by CTB and LT is intolerant to extension of the terminal galactose of GM1 but is somewhat tolerant to the extension of the internal sialic acid. Unlike CTB, LT does not display an absolute requirement for the internal sialic acid as shown by the weak binding of LT to asialo-GM1.

The glycolipid-binding specificities of CTB and LT reported here are generally in agreement with those previously reported using microtiter plate assays and TLC overlays (12, 27-29). However, the SPR/liposome method yielded quantitative data on rate constants and affinities which are not easily obtained using conventional approaches such as radiolabeled ligand binding and microtiter plate assays. The affinity derived for CTB binding to GM1 is similar to that obtained by Cuatrecasas (30) by measuring radiolabeled CT binding to cell membranes. Moreover, the toxin-receptor specificities observed by SPR are more consistent with the binding site features seen in crystal structures (2-4) than the less restricted specificities obtained by microtiter plate assays (29). For instance, the microtiter plate assay showed very good binding of LT to GM2 (29), which lacks the terminal galactose residue, and this finding is difficult to rationalize in light of the crystal structure of the CTB-GM1 oligosaccharide complex (2, 3).

Both CTB and LT showed a very high affinity for liposomes containing 1 and 2% GM1, provided the toxin concentrations are sufficiently low to give the maximum valency, presumably pentavalency, of attachment. Under these conditions, the off-rates are extremely slow. These toxins also had strong affinity for GD1b although in each instance the affinity was only one-tenth that observed for GM1. The SPR technique can easily detect interactions with affinities in the low micromolar range, indicating that there is no significant binding of CTB and LT to any of the other glycolipids tested (Fig. 6, A and B).

While the CT binding data presented here are generally in good agreement with previous studies (12-14, 27-29), they are not consistent with a recent SPR study of CT affinity and specificity for gangliosides (16). Kuziemko et al. (16) observed CT binding to several gangliosides with the following order of binding strength: GM1 > GM2 > GD1a > GM3 > GT1b > GD1b > asialo-GM1. This specificity profile is difficult to rationalize on the basis of the GM1 pentasaccharide-CTB crystal structure and the binding to GD1a, GM3, and asialo-GM1 contradicts binding specificities determined by other means (1). Most striking is the high affinity reported for GD1a binding (Kd = 31.8 pM); this ganglioside was used as a negative control in the analysis of ligand binding to CT by titration microcalorimetry (14) and was shown to give insignificant heat release. It is possible that the specificity differences observed with the two SPR methods may be partially related to potentially different modes of oligosaccharide presentation in the two lipid bilayer environments. The glycolipid surfaces used by Kuziemko et al. (16) were prepared by fusing 5 mol % glycolipid:95 mol % palmitoyloleoylglycero-3-phosphocholine to alkylthiol monolayer on the gold surface of the sensor chip to form planar hybrid bilayer membranes (31). There is considerable evidence that glycolipid carbohydrate can be modulated by the bilayer microenvironment (32).

The TT C-fragment specificities for gangliosides are quite different from those obtained by Holmgren et al. (27) and Ångström et al. (29), using microtiter plate formats. They reported similar specificities for GD1b, GT1b, and GQ1b whereas the SPR-liposome results indicated a slightly higher affinity for GD1b relative to GT1b and no binding to GQ1b. The observation that the affinity of TT C-fragment for its preferred ganglioside ligand is several orders of magnitude lower than that of CTB and LT for their preferred ganglioside ligands supports the view that gangliosides are not exclusive receptors for the clostridial neurotoxins (17, 33). The TT C-fragment interaction with its ganglioside receptor is presumably monovalent. Tetanus toxin is comprised of a 100-kDa heavy chain linked to a 50-kDa light chain bridged by a single interchain disulfide bridge. The light chain is responsible for the blockage of neurotransmitter release. The heavy chain is composed of two domains, the N-domain which is thought to mediate cell penetration and the C-domain which is responsible for neurospecific binding via the protein and ganglioside receptors (17).

The methodology described here should provide a powerful means of testing the effectiveness of inhibitors of protein-glycolipid interactions. The assay permits real time analysis of binding to membrane bound oligosaccharides and a means of pretesting conditions necessary for inhibition at cellular surfaces. Bacterial toxins are only one of a number of carbohydrate binding events that could be studied in this way. For example, inhibition of virus binding to cell surfaces could be monitored since it is known that virus particle binding can be followed by SPR (34). The system should also be amenable to the presentation of membrane proteins through the same LPS capture procedure. It should also be possible to simultaneously incorporate two ligands which would be useful in instances such as receptor binding by Clostridium botulinum type B neurotoxin which is thought to bind with high affinity to synaptotagmin, an integral membrane protein of synaptic vesicles, in association with the gangliosides GT1b and GD1a (33).


FOOTNOTES

*   This is National Research Council of Canada Publication 39538. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. Tel.: 613-990-0833; Fax: 613-941-1327; E-mail: roger.mackenzie{at}nrc.ca.
1    The abbreviations used are: LT, E. coli heat-labile enterotoxin; CT, cholera toxin; CTB, the pentameric B-subunit of cholera toxin; DMPC, dimyristoylphosphatidylcholine; LPS, lipopolysaccharide; RU, resonance unit; SPR, surface plasmon resonance; TLC, thin layer chromatography; TT, tetanus toxin; IgG, immunoglobulin G.

Acknowledgments

We thank Dr. Dennis Sprott and Chantal Dicaire for advice on the preparation of liposomes.


REFERENCES

  1. Karlsson, K.-A. (1995) Curr. Opin. Struct. Biol. 5, 622-635 [CrossRef][Medline] [Order article via Infotrieve]
  2. Merritt, E. A., Sarfaty, S., van den Akker, F., L'Hoir, C. L., Martial, J. A., and Hol, W. G. J. (1994a) Protein Sci. 3, 166-177 [Abstract/Free Full Text]
  3. Merritt, E. A., Sixma, T. K., Kalk, K. H., van Zanten, B. A. M., and Hol, W. G. J. (1994b) Mol. Microbiol. 13, 745-753 [Medline] [Order article via Infotrieve]
  4. Sixma, T. K., Pronk, S. E., Kalk, K. H., van Zanten, B. A. M., Berguis, A. M., and Hol, W. G. J. (1992) Nature 355, 561-564 [CrossRef][Medline] [Order article via Infotrieve]
  5. Sixma, T. K., Stein, P. E., Hol, W. G. J., and Read, R. J. (1993) Biochemistry 32, 191-198 [Medline] [Order article via Infotrieve]
  6. Sixma, T, K., Kalk, K. H., van Zanten, B. A. M., Dauter, Z., Kingma, J., Witholt, B., and Hol, W. G. J. (1993) J. Mol. Biol. 230, 890-918 [CrossRef][Medline] [Order article via Infotrieve]
  7. Fraser, M. E., Chernaia, M. M., Kozlov, Y. V., and James, M. N. G. (1994) Nature Struct. Biol. 1, 59-64 [Medline] [Order article via Infotrieve]
  8. Stein, P. E., Boodhoo, A., Tyrrell, G. J., Brunton, J. L., and Read, R. J. (1992) Nature 355, 748-750 [CrossRef][Medline] [Order article via Infotrieve]
  9. Stein, P. E., Boodhoo, A., Armstrong, G. D., Heerze, L. D., Cockle, S. A., Klein, M. H., and Read, R. J. (1994) Nature Struct. Biol. 1, 591-596 [Medline] [Order article via Infotrieve]
  10. Griffiths, S. L., Finkelstein, R. A., and Critchley, D. R. (1986) Biochem. J. 238, 313-322 [Medline] [Order article via Infotrieve]
  11. Orlandi, P. A., Critchley, D. R., and Fishman, P. H. (1994) Biochemistry 33, 12886-12895 [Medline] [Order article via Infotrieve]
  12. Teneberg, S., Hirst, T. R., Ångström, J., and Karlsson, K.-A. (1994) Glycoconjugate J. 11, 533-540 [Medline] [Order article via Infotrieve]
  13. Schön, A., and Freire, E. (1989) Biochemistry 28, 5019-5024 [Medline] [Order article via Infotrieve]
  14. Masserini, M., Freire, E., Palestini, P., Calappi, E., and Tettamanti, G. (1992) Biochemistry 31, 2422-2426 [Medline] [Order article via Infotrieve]
  15. St. Hilaire, P., Boyd, M. K., and Toone, E. J. (1994) Biochemistry 33, 14452-14463 [Medline] [Order article via Infotrieve]
  16. Kuziemko, G. M., Stroh, M., and Stevens, R. C. (1996) Biochemistry 35, 6375-6383 [CrossRef][Medline] [Order article via Infotrieve]
  17. Montecucco, C., and Schiavo, G. (1994) Mol. Microbiol. 13, 1-8 [Medline] [Order article via Infotrieve]
  18. Johnson, K. G., and Perry, M. B. (1976) Can. J. Microbiol. 22, 29-34 [Medline] [Order article via Infotrieve]
  19. Altman, E., and Bundle, D. R. (1994) Methods Enzymol. 247, 243-253 [Medline] [Order article via Infotrieve]
  20. Bundle, D. R., Eichler, E., Gidney, M. A. J., Meldal, M., Ragauskas, A., Sigurskjold, B. W., Sinnott, B., Watson, D. C., Yaguchi, M., and Young, N. M. (1994) Biochemistry 33, 5172-5182 [Medline] [Order article via Infotrieve]
  21. Jönsson, U., Fägerstam, L., Ivarsson, B., Johnsson, B., Karlsson, R., Lundh, K., Löfås, S., Persson, B., Roos, H., Rönnberg, I., Sjölander, S., Stenberg, E., Ståhlberg, R., Urbaniczky, C., Östlin, H., and Malmqvist, M. (1991) BioTechniques 11, 620-627 [Medline] [Order article via Infotrieve]
  22. Stenberg, E., Persson, B., Roos, H., and Urbaniczky, C. (1991) J. Colloid Interface Sci. 143, 513-526
  23. O'Shannessy, D. J., Brigham-Burke, M., Soneson, K. K., Hensley, P., and Brooks, I. (1993) Anal. Biochem. 212, 457-468 [CrossRef][Medline] [Order article via Infotrieve]
  24. MacKenzie, C. R., Hirama, T., Deng, S., Bundle, D. R., Narang, S. A., and Young, N. M. (1996) J. Biol. Chem. 271, 1527-1533 [Abstract/Free Full Text]
  25. Yiu, S. C. K., and Lingwood, C. A. (1992) Anal. Biochem. 202, 188-192 [Medline] [Order article via Infotrieve]
  26. Masson, L., Mazza, A., and Brousseau, R. (1994) Anal. Biochem. 218, 405-412 [CrossRef][Medline] [Order article via Infotrieve]
  27. Holmgren, J., Elwing, H., Fredman, P., and Svennerholm, L. (1980) Eur. J. Biochem. 106, 371-379 [Medline] [Order article via Infotrieve]
  28. Fukuta, S., Magnani, J. L., Twiddy, E. D., Holmes, R. K., and Ginsburg, V. (1988) Infect. Immun. 56, 1748-1753 [Medline] [Order article via Infotrieve]
  29. Ångström, J., Teneberg, S., and Karlsson, K.-A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11859-11863 [Abstract/Free Full Text]
  30. Cuatrecasas, P. (1973) Biochemistry 12, 3547-3558 [Medline] [Order article via Infotrieve]
  31. Plant, A. L., Brigham-Burke, M., Petrella, E. C., and O'Shannessy, D. J. (1995) Anal. Biochem. 226, 342-348 [CrossRef][Medline] [Order article via Infotrieve]
  32. Lingwood, C. A. (1996) Glyconjugate J. 13, 495-503 [Medline] [Order article via Infotrieve]
  33. Nishiki, T., Tokuyama, Y., Kamata, Y., Nemoto, Y., Yoshida, A., Sato, K., Sekiguchi, M., Takahashi, M., and Kozaki, S. (1996) FEBS Lett. 378, 253-257 [CrossRef][Medline] [Order article via Infotrieve]
  34. Pellequer, J. L., and Van Regenmortel, M. H. V. (1993) J. Immunol. Methods 166, 133-143 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.